Skip to main content
SpringerLink
Log in

Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens

  • Concise Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

In two prospective, randomized studies intravenous (IV)/oral (PO) moxifloxacin (400 mg q.i.d.) was compared to IV/PO antimicrobial comparator agents for the treatment of hospitalized patients with community-acquired pneumonia. Reported here are the pooled data for the sub-population with atypical pathogens. Of 101 intent-to-treat patients with atypical pathogens, a total of 39 moxifloxacin-treated and 47 comparator-treated subjects were microbiologically valid and included in the analysis. Clinical and bacteriological success rates were 95% for the moxifloxacin-treated and 94% for the comparator-treated subjects at the test-of-cure visit. The results indicate IV/PO moxifloxacin (400 mg q.i.d.) is an effective monotherapy for patients with CAP due to atypical pathogens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Plouffe JF (2000) Importance of atypical pathogens of community-acquired pneumonia. Clin Infect Dis 31(Suppl 2):35–39

    Article  Google Scholar 

  2. File TM Jr, Tan JS, Plouffe JF (1998) The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect Dis Clin North Am 12:569–592

    PubMed  Google Scholar 

  3. Lim WS, Macfarlane JT, Boswell TC, Harrison TG, Rose D, Leinonen M, Saikku P (2001) Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 56:296–301

    Article  CAS  PubMed  Google Scholar 

  4. Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M (1999) Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 106:385–390

    Article  CAS  PubMed  Google Scholar 

  5. Porath A, Schlaeffer F, Lieberman D (1997) The epidemiology of community-acquired pneumonia among hospitalized adults. J Infect 34:41–48

    CAS  PubMed  Google Scholar 

  6. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN (1996) Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 101:508–515

    Article  CAS  PubMed  Google Scholar 

  7. Marston BJ, Plouffe JF, File TM Jr et al (1997) Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Community-Based Pneumonia Incidence Study Group. Arch Intern Med 157:1709–1718

    Article  CAS  PubMed  Google Scholar 

  8. Mandel LA (2000) Guidelines for community-acquired pneumonia: a tale of 2 countries. Clin Infect Dis 31:422–425

    Article  PubMed  Google Scholar 

  9. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C, Infectious Diseases Society of America (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405–1433

    Article  PubMed  Google Scholar 

  10. Niederman MS, Mandell LA, Anzueto A et al (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730–1754

    CAS  PubMed  Google Scholar 

  11. Finch R, Schurmann D, Collins O et al (2002) A randomized controlled trial of sequential intravenous (IV) and oral moxifloxacin compared with sequential IV and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 46:1746–1754

    Article  CAS  PubMed  Google Scholar 

  12. File TM, Larsen LS, Fogarty CM et al (2001) Safety and efficacy of sequential (IV to PO) moxifloxacin for the treatment of community-acquired pneumonia in hospitalized patients. Todays Ther Trends 19:251–270

    Google Scholar 

  13. Niederman MS, Bass JB, Campbell GD et al (1993) Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 148:1418–1426

    CAS  PubMed  Google Scholar 

  14. Norrby SR, Petermann W, Willcox PA et al (1998) A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 30:397–404

    Article  CAS  PubMed  Google Scholar 

  15. Ruiz M, Ewig S, Torres A et al (1999) Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 160:923–929

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We wish to thank all of the dedicated investigators who participated in the multinational and the North American clinical trials. We also thank B. Shearer and T. Tartaglione for editorial contributions. All experiments were performed in compliance with the current laws of the country in which they were conducted. This work was supported by a research grant from Bayer Pharmaceuticals Corporation, West Haven, CT, USA.

Author information

Authors and Affiliations

  1. Universitätsklinikum Carl Gustav Carus/Technische Universität, Fetscherstrasse 74, 01307, Dresden, Germany

    G. Hoeffken

  2. UCLA Medical Center, 14445 Olive View Drive, Sylmar, CA, 91342, USA

    D. Talan

  3. Fusion Clinical Trials, Red Bank, NJ, USA

    L. S. Larsen

  4. Hospital Fleury, 2180 Fleury Street, Montreal, QC, Canada, H2B 1K3

    S. Peloquin

  5. Bayer Corporation, 400 Morgan Lane, West Haven, CT, 06516, USA

    S. H. Choudhri, D. Haverstock, P. Jackson & D. Church

Authors
  1. G. Hoeffken
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Talan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. S. Larsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Peloquin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. H. Choudhri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Haverstock
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Church
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Hoeffken.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoeffken, G., Talan, D., Larsen, L.S. et al. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens. Eur J Clin Microbiol Infect Dis 23, 772–775 (2004). https://doi.org/10.1007/s10096-004-1214-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-004-1214-5

Keywords

Search

Navigation